Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Researchers at Massachusetts Institute of Technology (MIT) and the University of Colorado at Denver in the US are working on repurposing an existing blood clots drug to help patients at risk of respiratory failure.

The drug is a tissue plasminogen activator (tPA) used to help heart attack and stroke patients. Three hospitals in Massachusetts and Colorado intend to test the drug in severely ill Covid-19 patients.

According to MIT, the project comes from data of Chinese and Italian studies that Covid-19 is characterised by blood clotting linked to respiratory failure.

MIT science professor Michael Yaffe said: “If this were to work, which I hope it will, it could potentially be scaled up very quickly because every hospital already has it in their pharmacy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We don’t have to make a new drug, and we don’t have to do the same kind of testing that you would have to do with a new agent. This is a drug that we already use. We’re just trying to repurpose it.”

The researchers plan to assess intravenous tPA in patients under the FDA’s compassionate use programme. If the drug yields encouraging data in initial patients, its use may be expanded further.